Home > Boards > US Listed > Biotechs > Agile Therapeutics, Inc. (AGRX)

5-8% of the 4.1B market equates to ~205-330M

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pnnymn Member Profile
Member Level 
Followed By 42
Posts 3,581
Boards Moderated 6
Alias Born 07/10/05
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/14/2021 8:31:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/11/2021 6:31:27 AM
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference GlobeNewswire Inc. - 1/4/2021 12:18:15 PM
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/21/2020 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/7/2020 4:31:05 PM
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol)... GlobeNewswire Inc. - 12/7/2020 7:30:00 AM
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethin... GlobeNewswire Inc. - 11/30/2020 9:11:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/23/2020 5:01:26 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 11/23/2020 4:46:36 PM
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference GlobeNewswire Inc. - 11/23/2020 10:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2020 4:17:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2020 4:11:23 PM
Agile Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire Inc. - 11/12/2020 4:05:00 PM
Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial... GlobeNewswire Inc. - 11/4/2020 7:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/15/2020 6:30:17 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 10/2/2020 4:32:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 10/1/2020 4:26:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/28/2020 4:11:13 PM
Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire Inc. - 9/22/2020 11:40:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/21/2020 4:10:58 PM
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference GlobeNewswire Inc. - 9/9/2020 8:00:10 AM
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020 GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control GlobeNewswire Inc. - 9/2/2020 9:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2020 5:00:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2020 4:16:35 PM
pnnymn Member Level  Friday, 10/16/20 10:35:56 PM
Re: None
Post # of 1056 
5-8% of the 4.1B market equates to ~205-330M annual sales. If we achieve the lower end 205M annual, trading at 3x sales would put us at ~$7 and 5x sales would put our valuation at around 1B or ~$12. I would assume in the long run that the former valuation is Agile’s worst case scenario. The realistic best case scenario would be trading at 5x 330M annual sales, which would put us at ~$19.5.

***Disclaimer & Disclosure***: I make no guarantee as to the accuracy or validity of information in this message. Messages posted reflect my own opinions and/or those of others, and are posted for entertainment purposes only.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences